Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus
Obesity and diabetes mellitus are prevalent metabolic disorders that have a detrimental impact on overall health. In this regard, there is now a clear link between these metabolic disorders and compromised bone health. Interestingly, both obesity and diabetes lead to elevated risk of bone fracture w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-03-01
|
| Series: | Clinical Medicine Insights: Endocrinology and Diabetes |
| Online Access: | https://doi.org/10.1177/11795514241238059 |
| _version_ | 1797263169557626880 |
|---|---|
| author | Asif Ali Peter R Flatt Nigel Irwin |
| author_facet | Asif Ali Peter R Flatt Nigel Irwin |
| author_sort | Asif Ali |
| collection | DOAJ |
| description | Obesity and diabetes mellitus are prevalent metabolic disorders that have a detrimental impact on overall health. In this regard, there is now a clear link between these metabolic disorders and compromised bone health. Interestingly, both obesity and diabetes lead to elevated risk of bone fracture which is independent of effects on bone mineral density (BMD). In this regard, gastrointestinal (GIT)-derived peptide hormones and their related long-acting analogues, some of which are already clinically approved for diabetes and/or obesity, also seem to possess positive effects on bone remodelling and microarchitecture to reduce bone fracture risk. Specifically, the incretin peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as glucagon-like peptide-2 (GLP-2), exert key direct and/or indirect benefits on bone metabolism. This review aims to provide an initial appraisal of the relationship between obesity, diabetes and bone, with a focus on the positive impact of these GIT-derived peptide hormones for bone health in obesity/diabetes. Brief discussion of related peptides such as parathyroid hormone, leptin, calcitonin and growth hormone is also included. Taken together, drugs engineered to promote GIP, GLP-1 and GLP-2 receptor signalling may have potential to offer therapeutic promise for improving bone health in obesity and diabetes. |
| first_indexed | 2024-04-25T00:08:44Z |
| format | Article |
| id | doaj.art-1101955a3b23497eb912bf8cd44725b0 |
| institution | Directory Open Access Journal |
| issn | 1179-5514 |
| language | English |
| last_indexed | 2024-04-25T00:08:44Z |
| publishDate | 2024-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Endocrinology and Diabetes |
| spelling | doaj.art-1101955a3b23497eb912bf8cd44725b02024-03-13T17:03:20ZengSAGE PublishingClinical Medicine Insights: Endocrinology and Diabetes1179-55142024-03-011710.1177/11795514241238059Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes MellitusAsif AliPeter R FlattNigel IrwinObesity and diabetes mellitus are prevalent metabolic disorders that have a detrimental impact on overall health. In this regard, there is now a clear link between these metabolic disorders and compromised bone health. Interestingly, both obesity and diabetes lead to elevated risk of bone fracture which is independent of effects on bone mineral density (BMD). In this regard, gastrointestinal (GIT)-derived peptide hormones and their related long-acting analogues, some of which are already clinically approved for diabetes and/or obesity, also seem to possess positive effects on bone remodelling and microarchitecture to reduce bone fracture risk. Specifically, the incretin peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as glucagon-like peptide-2 (GLP-2), exert key direct and/or indirect benefits on bone metabolism. This review aims to provide an initial appraisal of the relationship between obesity, diabetes and bone, with a focus on the positive impact of these GIT-derived peptide hormones for bone health in obesity/diabetes. Brief discussion of related peptides such as parathyroid hormone, leptin, calcitonin and growth hormone is also included. Taken together, drugs engineered to promote GIP, GLP-1 and GLP-2 receptor signalling may have potential to offer therapeutic promise for improving bone health in obesity and diabetes.https://doi.org/10.1177/11795514241238059 |
| spellingShingle | Asif Ali Peter R Flatt Nigel Irwin Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus Clinical Medicine Insights: Endocrinology and Diabetes |
| title | Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus |
| title_full | Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus |
| title_fullStr | Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus |
| title_full_unstemmed | Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus |
| title_short | Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus |
| title_sort | gut derived peptide hormone analogues and potential treatment of bone disorders in obesity and diabetes mellitus |
| url | https://doi.org/10.1177/11795514241238059 |
| work_keys_str_mv | AT asifali gutderivedpeptidehormoneanaloguesandpotentialtreatmentofbonedisordersinobesityanddiabetesmellitus AT peterrflatt gutderivedpeptidehormoneanaloguesandpotentialtreatmentofbonedisordersinobesityanddiabetesmellitus AT nigelirwin gutderivedpeptidehormoneanaloguesandpotentialtreatmentofbonedisordersinobesityanddiabetesmellitus |